The Pharmaceutical industry is not a constant. It is rather changing and receiving plenty of internal and external impacts. In clinical research sometimes the impacts derive directly from trial participants and often the lack of enough trials can turn into a major issue. Because there is an enormous emphasis on Managed Care Organizations, the research sectors are migrating from their currently adopted environments, while trying to achieve partnership with MCOs. But are this kinds of partnerships easily achievable and how exactly can they contribute to clinical studies?
Building a stable relationship is very important when we talk about delivering proportionate and equally beneficial results to both parties. But this is not something very easy to accomplish. Especially if we consider the very fact that the research team and those who represent the Managed Care Organization do not share many common grounds. There are some significance which are said to be able to help both sides destroy the walls of opposition. Being two separate cultures with different motives, there are a few things that researchers and MCO representatives are expected to do. The first thing includes establishing corresponding agendas which cover the needs of both sites. After that, there should be stable communication and exchange of information through informal and formal contacts with colleagues. Interestingly enough, informal contacts between research and non-research academics can provide important information regarding:
– planned procedures which, in consequence, can help them define the common grounds and shared views in the research design and the organizational architecture of the Managed Care Organization
– anticipated and present-time alterations in management and operation
– ongoing clinical studies and, respectively, ongoing treatments carried out by MCOs
Lastly, when there is already an established communication, point out possible communication issues becomes essential for the adequate and optimal cooperation. What is more, this way any types of misunderstanding between collaborators can be avoid.
In conclusion, both clinical trial organizations and managed care organizations are in a constant process of developing and changing. During these processes they are being affected by a number of external and internal factors. Despite the fact that they are different in their very own objectives, creating a common relationship is beneficial to both of them. One of the biggest drawbacks in clinical researches is not having enough participants. And when MCOs gain more and more popularity among people, such organizations are becoming not only subject-sources but also contributors and collaborators to clinical trials conductors.
Comments